Olmesartan medoxomil-induced acute renal failure in a premature newborn following maternal exposure during pregnancy: A case report and review of the literature

NDT Plus

Volumn 2, Issue 4, 2009, Pages 295-297

  Georgaki Angelaki, Eleni ^a   Stergiou, Nicolaos ^a   Naoum, Ekaterini ^b   Papassotiriou, Ioannis ^c   Anagnostakou, Marina ^b  

^a Department of Pediatric Nephrology ^*  (United States)

^b Neonatal Intensive Care Unit   (Australia)

^c AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

acute renal failure; oligohydramnios; olmesartan medoxomil

Indexed keywords

BETAMETHASONE; CREATININE; GROWTH FACTOR RECEPTOR; OLMESARTAN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLOOD PRESSURE; CASE REPORT; CREATININE BLOOD LEVEL; DYSPNEA; ELECTROLYTE INTAKE; ENVIRONMENTAL EXPOSURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; KIDNEY FUNCTION; NEWBORN; OLIGOHYDRAMNIOS; OLIGURIA; PATENT DUCTUS ARTERIOSUS; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY TRACT INTUBATION;

EID: 77955965818     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfp045     Document Type: Article

References (20)

1. Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005; 65(Suppl 2): 29-39
2. Ḧorl WH. ACE inhibitors and the kidney. Wien Med Wochenschr 1996; 146: 231-235
3. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 2006; 82: 23-28
4. Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 2005; 73: 123-130
5. Knott PD, Thorpe SS, Lamont CAR. Congenital renal dysgenesis possibly due to captopril. Lancet 1989; 1: 451
6. Kreft-Jais C, Plouin C, Tchobroutsky C et al. Angiotensin-converting enzyme inhibitors during pregnancy: a survey of 22 patients given captopril and nine given enalapril. Br J Obstet Gynaecol 1988; 95: 420-422
7. Sedman AB, Kershaw DB, Bunchman SR. Recognition and management of angiotensin converting enzyme inhibitor fetopathy. Pediatr Nephrol 1995; 9: 382-385
8. Gardner SF, Franks AM. Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Ann Pharmacother 2003; 37: 99-105
9. Bos-ThompsonMA,Hillaire-Buys D, Muller F et al. Fetal toxic effects of angiotensin II receptor antagonist: case report and follow-up after birth. Ann Pharmacother 2005; 39: 157-161
10. Hilgers KF, Norwood VF, Gomez RA. Angiotensin's role in renal development. Semin Nephrol 1997; 17: 492-501
11. Broughton-Pipkin F, Symonds EM, Turner TE. Possible risk with captopril during pregnancy: some animal data. Lancet 1980; 1 : 1256
12. Duminy PC, Burger PD. Fetal abnormality associated with the use of captopril during pregnancy. S AfrMed J 1981; 60: 805
13. Nightingale SL. Warning on the use of ACE inhibitors in second and third trimester of pregnancy. JAMA 1992; 267: 2445
14. Schaefer C. Angiotensin II receptor antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res Part A Clin Mol Teratol 2003; 67: 591-594
15. Biswas PN, Wilton LV, Shakir SW. The safety of valsartan: results of postmarketing surveillance study on 12,881 patients in England. J Hum Hypertens 2002; 16: 795-803
16. Chung NA, Lip GYH, Beevers M et al. Angiotensin II receptor inhibitors in pregnancy. Lancet 2001; 357: 1620
17. Celentano C, Prefumo F, Di-Vera E et al. Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker. Pediatr Nephrol 2008; 23: 233-234
18. Martinovic J, Benachi A, Laurent N et al. Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet 2001; 358: 241-242
19. Saji H, Yamanaka M, Hagiwara A et al. Losartan and fetal toxic effects. Lancet 2001; 357: 63
20. Tufro-McReddie A, Johns DW, Geary KM. Angiotensin II type 1 receptor: role in renal growth and gene expression during normal development. Am J Physiol 1994; 266: F911-F918